Exicure Inc is a clinical-stage biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA ... Exicure Inc is a clinical-stage biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology. Show more
Exicure, Inc. (βExicureβ or the βCompanyβ) (Nasdaq: XCUR), announced today that on July 31, 2024, the Company received formal notice that the Nasdaq Hearings Panel (βPanelβ) has determined to...
Exicure, Inc. (Nasdaq: XCUR, the βCompanyβ), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0334 | 6.93521594684 | 0.4816 | 0.935 | 0.41 | 14504381 | 0.64916457 | CS |
4 | 0.2 | 63.4920634921 | 0.315 | 0.95 | 0.2914 | 5882592 | 0.59441363 | CS |
12 | 0.057 | 12.4454148472 | 0.458 | 0.95 | 0.2914 | 2425095 | 0.57654739 | CS |
26 | -0.035 | -6.36363636364 | 0.55 | 0.95 | 0.2914 | 1204161 | 0.58320336 | CS |
52 | -0.435 | -45.7894736842 | 0.95 | 0.9975 | 0.2914 | 808013 | 0.58479799 | CS |
156 | -0.885 | -63.2142857143 | 1.4 | 3.24 | 0.0846 | 2611565 | 0.27981889 | CS |
260 | -2.455 | -82.6599326599 | 2.97 | 3.84 | 0.0846 | 1801299 | 0.51995425 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.